Original language | English (US) |
---|---|
Pages (from-to) | 157-181 |
Number of pages | 25 |
Journal | Rheumatic Disease Clinics of North America |
Volume | 48 |
Issue number | 1 |
DOIs | |
State | Published - Feb 2022 |
Funding
Dr K. Ardalan receives salary support from Cure JM Foundation to assist with clinical trial design with ReveraGen BioPharma but does not receive any funding or compensation from ReveraGen BioPharma; he also receives salary/grant support from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Rheumatology Research Foundation. Dr D.M. Lloyd-Jones has no commercial or financial conflicts to disclose. Dr L.E. Schanberg receives salary support from CARRA, Inc; DSMB member for Sanofi and UCB; grant support from PCORI and BMS. Dr K. Ardalan receives salary support from Cure JM Foundation to assist with clinical trial design with ReveraGen BioPharma but does not receive any funding or compensation from ReveraGen BioPharma; he also receives salary/grant support from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Rheumatology Research Foundation . Dr D.M. Lloyd-Jones has no commercial or financial conflicts to disclose. Dr L.E. Schanberg receives salary support from CARRA, Inc ; DSMB member for Sanofi and UCB; grant support from PCORI and BMS .
Keywords
- Cardiovascular disease
- Cardiovascular health
- Juvenile dermatomyositis
- Juvenile idiopathic arthritis
- Pediatric rheumatology
- Systemic lupus erythematosus
ASJC Scopus subject areas
- Rheumatology